{"id":"ser120-nasal-spray-500-ng-day","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SER120 is a Phase 3 candidate from Serenity Pharmaceuticals administered as a nasal spray at 500 ng/day. Without publicly disclosed mechanism information, the specific molecular target and therapeutic pathway remain undetermined. Further clinical trial data would be needed to characterize its pharmacological action.","oneSentence":"SER120 is an investigational nasal spray formulation with an unknown mechanism of action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:07.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01259128","phase":"PHASE3","title":"Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia","status":"COMPLETED","sponsor":"Serenity Pharmaceuticals, Inc.","startDate":"2010-04","conditions":"Nocturia","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SER120 Nasal Spray 500 ng/day","genericName":"SER120 Nasal Spray 500 ng/day","companyName":"Serenity Pharmaceuticals, Inc.","companyId":"serenity-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}